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Regulation of hepcidin expression 
by inflammation-induced activin B
Yohei Kanamori1, Makoto Sugiyama2, Osamu Hashimoto3, Masaru Murakami4, Tohru Matsui1 
& Masayuki Funaba1
Activin B is induced in response to inflammation in the liver and enhances hepcidin expression, but 
the source of activin B and the molecular mechanism underlying hepcidin induction are not clear yet. 
Lipopolysaccharide (LPS)-induced inflammation induced inhibin βB but not inhibin α or inhibin βA 
expression in the liver, implicating activin B induction. Immunoreactive inhibin βB was detected in 
endothelial cells and Kupffer cells in LPS-treated liver. Activin B, but not activin A or activin AB, directly 
increased hepcidin expression. Activin B induced phosphorylation and activation of Smad1/5/8, the 
BMP-regulated (BR)-Smads. The stimulation of hepcidin transcription by activin B was mediated by 
ALK2 and ActRIIA, receptors for the TGF-β family. Unexpectedly, activin B-induced hepcidin expression 
and BR-Smad phosphorylation were resistant to the effects of LDN-193189, an ALK2/3/6 inhibitor. 
ALK2 and ActRIIA complex formation in response to activin B may prevent the approach of LDN-193189 
to ALK2 to inhibit its activity. Activin B also induced phosphorylation of Smad2/3, the TGF-β/activin-
regulated (AR)-Smad, and increased expression of connective tissue growth factor, a gene related to 
liver fibrogenesis, through ALK4 and ActRIIA/B. Activin B-induced activation of the BR-Smad pathway 
was also detected in non-liver-derived cells. The present study reveals the broad signaling of activin B, 
which is induced in non-parenchymal cells in response to hepatic inflammation, in hepatocytes.
Hepcidin, a liver-derived peptide hormone, regulates systemic iron homeostasis. Iron overload induces the 
expression of hepcidin, which binds to and degrades ferroportin, the only known iron exporter, leading to a 
reduction in serum iron concentrations1,2. Hepcidin expression is also induced by inflammation, and hepcidin is 
suggested to be responsible for inflammation-induced anemia3. Iron overload and inflammation are thought to 
be central regulators of hepcidin expression4,5. Hepcidin expression is primarily regulated at the transcriptional 
level, whereby BMP6, a member of the BMP subgroup of the TGF-β superfamily that is produced in response to 
iron overload, increases hepcidin transcription6,7. Other members of the BMP subgroup, including BMP2, BMP4 
and BMP9, also up-regulate hepcidin expression8. By contrast, interleukin (IL)-6, which is produced in response 
to inflammation9, plays a role in the inflammation-induced transactivation of hepcidin5,10.
The TGF-β family is divided into three subgroups: TGF-β , activin and BMP subgroups. All members signal 
in a similar fashion, whereby the ligands bind to specific type I receptors and type II receptors; type I receptors 
are called activin receptor-like kinases (ALKs), and type II receptors consist of Tβ RII, ActRIIA, ActRIIB and 
BMPRII. Ligand and receptor complex formation activates a type I receptor serine/threonine kinase, leading to 
the phosphorylation of a receptor-regulated (R)-Smad. Phosphorylated R-Smad forms a complex with Smad4 and 
regulates target gene transcription11–13. The current signaling model indicates that the type I receptor and type 
II receptor for the TGF-β subgroup are ALK5 and Tβ RII, respectively, and the activin subgroup signals through 
the type I receptor ALK4/7 and the type II receptors ActRIIA and ActRIIB. The type I receptors of the BMP sub-
group are ALK2/3/6, and the type II receptors are ActRIIA, ActRIIB and BMPRII. R-Smads are categorized as 
activin/TGF-β pathway-specific R-Smads (AR-Smad: Smad2 and Smad3) and BMP pathway-specific R-Smads 
(BR-Smad: Smad1, Smad5 and Smad8). Members of the TGF-β and activin subgroups signal via AR-Smads, 
whereas those of the BMP subgroup signal via BR-Smads11–13.
BMP pathway-mediated hepcidin transcription is also involved in inflammation-induced hepcidin transcrip-
tion. The hepcidin expression induced in the liver in response to lipopolysaccharide (LPS), a potent stimula-
tor of inflammation, was decreased in IL-6 null mice, but still responded to LPS14. In addition, treatment with 
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LDN-193189, an inhibitor of ALK2/3/6 that suppresses BR-Smad-mediated signaling15, decreased hepatic hep-
cidin expression in rats and mice with experimentally induced anemia of inflammation16,17. These results suggest 
that a molecule(s) eliciting BMP signaling is produced during inflammation to induce hepcidin expression.
Previously, Jones et al.18 and Besson-Fournier et al.19 revealed the genetic induction of inhibin β B in 
LPS-treated liver. In addition, Besson-Fournier et al.19 showed that activin B, a homodimer of inhibin β B and 
a member of the activin subgroup of the TGF-β family20, stimulated hepcidin transcription through BMP path-
way activation. ALK3 transmits the activin B-mediated signal to up-regulate hepcidin expression19. These results 
suggest that activin B is one molecule responsible for inflammation-induced hepcidin expression via the BMP 
pathway. Consistent with these results, Canali et al.21 also reported that activin B stimulated the BMP-mediated 
signaling pathway and hepcidin transcription in Hep3B hepatocytes. However, the mechanism underlying activin 
B-induced hepcidin expression is controversial. Canali et al.21 suggested ALK2 as a primary signal receptor to 
elicit hepcidin transcription. Furthermore, the source of activin B produced during inflammation is unknown. 
The objective of this study is to identify (1) the localization of activin B in response to LPS, (2) the regulation of 
hepatic hepcidin expression by activin B, and (3) the activin B-induced signaling pathway.
Results
Activin B is induced in the liver in response to LPS treatment. We first examined the expression and 
localization of inhibin subunits in LPS-treated livers. Activin is a homo- or heterodimer of the inhibin β subunit, 
whereas structurally related inhibin is a heterodimer of the inhibin α subunit and β subunits20. Inhibin has an 
opposite effect on follicle-stimulating hormone release from the pituitary to that of activin22,23, and it does not 
transmit its signal via Smad20. Consistent with previous studies18,19, LPS induced the hepatic expression of inhibin 
β B, whereas inhibin β A expression decreased (Fig. 1A). The transcript levels of inhibin β C and β E in the liver were 
also decreased by LPS, whereas LPS did not affect the expression of inhibin α .
Immunoreactive inhibin β B was detected in some endothelial cells and Kupffer cells resided in central vein, 
interlobular arteriovenous and sinusoid in LPS-treated liver, whereas faint staining was detected in central vein 
and interlobular arteriovenous endothelial cells (Fig. 1B, Table 1); inhibin β B-positive cells were also positive for 
F4/80, a macrophage marker24, or CD31, a molecule predominantly expressed in endothelial cells25. Furthermore, 
Figure 1. Activin B induction in LPS-treated liver. C57BL/6 mice were intraperitoneally injected with PBS 
or with LPS (5 mg/kg). At 6 h post-injection, livers were recovered. (A) Expression levels of inhibin subunits 
(A) were examined by RT-qPCR analysis, and the expression levels in the control mice were set at 1. Mean ± SE 
(n = 4). * and **P < 0.05 and P < 0.01, respectively, vs. PBS-treated liver. (B) Immunolocalization of inhibin β 
B was examined by immunohistochemistry. A representative result of livers from LPS-treated mice is shown. 
Upper: localization of inhibin β B-positive cells. Middle: localization of F4/80- or CD31-positive cells. Lower: 
hematoxylin-eosin (H–E) staining of the serial section of the immunohistochemical image shown above. 
Arrowheads and arrows indicate Kupffer cells and sinusoidal endothelial cells, respectively. Arrowheads or 
arrows in black indicate double positive for inhibin β B and F4/80 or inhibin β B and CD31, respectively. Bar: 
50 μ m.
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strong staining was detected in the vessel lumen in LPS-treated livers, and no staining was detected in hepatic 
stellate cells. Similar results were obtained by centrifugation-based separation of liver cells. Inhibin β B mRNA 
was predominantly detected in the Kupffer cell/endothelial cell-rich fraction and endothelial cell-rich fraction 
(Supplementary Fig. S1A). LPS did not change the immunoreactivity of anti-inhibin α or β A antibody signifi-
cantly. Immunoreactive inhibin α and β A were predominantly detected in hepatocytes and vessel lumen, whereas 
endothelial cells and Kupffer cells were not stained (Table 1). Taking the regulatory expression and immunolocal-
ization of inhibin subunits in LPS-treated liver together with the gene induction of proinflammatory cytokines 
(Supplementary Fig. S1B), these results suggest that hepatic inflammation induces the production of activin B, a 
homodimer of inhibin β B, in vascular endothelial cells and Kupffer cells; the presence of activin B protein should 
be clarified in future.
Activin B increases hepcidin expression via BMP-responsive elements but not the STAT-binding 
site. We next examined changes in hepcidin expression with time after treatment with activin B or BMP2 
in rat primary hepatocytes. Consistent with previous results19,21, activin B increased the hepcidin transcript 
levels (Fig. 2A). Significant up-regulation of hepcidin expression was detected after 4 h of activin B treatment, 
which was slightly quicker than BMP2-induced hepcidin expression; BMP2 treatment for 4 h did not signifi-
cantly increase hepcidin expression. Comparable hepcidin induction was detected at 12 h in activin B-treated 
cells and BMP2-treated cells. BMP-induced hepcidin expression is mediated by phosphorylation and activation 
of BR-Smad4,5. Thus, we explored the phosphorylation of Smad1/5/8 by activin B treatment. As shown in Fig. 2B, 
activin B stimulated the phosphorylation of Smad1/5/8 within 30 min after the treatment, and the phospho-
rylation continued for at least 12 h; the kinetics of Smad1/5/8 phosphorylation was similar to that seen with 
BMP2 treatment. In addition to Smad1/5/8 phosphorylation, activin B induced Smad2 and Smad3 phospho-
rylation. Activin B and BMP2 increased hepcidin expression (Fig. 2C) and Smad1/5/8 phosphorylation in a 
dose-dependent manner (Fig. 2D); both hepcidin expression and Smad1/5/8 phosphorylation levels increased 
with increasing concentrations of activin B and BMP2. Treatment with cycloheximide, a protein synthesis 
inhibitor26, did not affect activin B-mediated hepcidin induction, whereas the hepcidin induction by BMP2 was 
cycloheximide-sensitive (Fig. 2E).
The activin B-induced hepcidin expression was regulated at the transcriptional level. Activin B 
induced Smad1/5/8 phosphorylation in HepG2 cells with a similar time-course as in primary hepatocytes 
(Supplementary Fig. S2A), and it stimulated the expression of hepcidin(-2018)-luc in a dose-dependent man-
ner in HepG2 cells (Supplementary Fig. S2B). To evaluate the role of the BMP pathway in activin B-mediated 
hepcidin transcription, the effects of mutations in the BMP-responsive elements (BMP-REs) in the hepcidin 
promoter were evaluated. Previous studies have shown that there are two possible BMP-REs: BMP-RE1, span-
ning nt − 155 to nt − 150, and BMP-RE2, spanning nt − 1678 to nt − 167327,28. Mutations of either BMP-RE 
decreased the basal hepcidin transcription, and the fold-induction of activin B stimulation was partially 
reduced (Supplementary Fig. S2C). Responsiveness to activin B was lost due to mutations of both BMP-RE1 and 
BMP-RE2, suggesting that similar to BMP, activin B stimulates hepcidin transcription via BMP-REs through the 
induction of BR-Smad phosphorylation and activation. Hepcidin transcription is also positively regulated via 
the STAT-binding site (STAT-BS) spanning nt − 143 to nt − 13429, but mutations in the STAT-BS did not change 
responsiveness to activin B (Supplementary Fig. S2D). Consistent with the results and unlike IL-6, activin B did 
not stimulate STAT3 phosphorylation (Supplementary Fig. S2E).
Neither activin A nor activin AB confers hepcidin transcription. Although several dimers of inhibin 
β B with inhibin subunits are possible, thus far, inhibin B30 (a heterodimer of inhibin α and inhibin β B), activin 
AB22 (a heterodimer of inhibin β A and inhibin β B) and activin B31 (a homodimer of inhibin β B) have been puri-
fied from natural sources. We examined whether similar to activin B, activin A or activin AB induces hepcidin 
transcription.
Neither activin AB nor activin A stimulated transcription of hepcidin(-2018)-luc within the range of tested 
concentrations, whereas activin B increased luciferase expression in a dose-dependent manner (Fig. 2F). All three 
activins stimulated CAGA-luc, a representative activin-responsive reporter mediated by activated AR-Smad32 
(Fig. 2G). Activin B but not activin A or activin AB induced phosphorylation of Smad1/5/8, whereas all activin 
isoforms stimulated Smad2/3 phosphorylation with comparable potency (Fig. 2H). These results suggest that 
Inhibin α Inhibin βA Inhibin βB
Control LPS Control LPS Control LPS
Hepatocytes + + ± ± − ± 
Kupffer cells − − − ± − + 
Hepatic stellate cells ± ± − − − − 
Endothelial cells
 Central vein − − − − ± + + 
 Interlobular arteriovenous − − − − ± + + 
 Sinusoid − − − − − + 
Vessel lumen ± − ± ± + + + 
Table 1.  Immunolocalization of inhibin subunits. − : Negative, ± : Faint staining, + : Moderate staining,  
+ + : Intense staining.
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homodimerization of inhibin β B is required for the stimulation of hepcidin transcription. Activin A and activin 
AB were purified from follicular fluid, whereas activin B was purified from cells recombinantly expressing inhibin 
β B; because it is undeniable that source of activin isoforms affects the results, use of the ligands prepared similarly 
may be helpful in future studies.
ALK2 and ActRIIA are responsible for activin B-mediated hepcidin transcription. Next, we 
explored which receptors elicit hepcidin transcription induced by activin B. To this end, possible receptors for 
activin B were individually knocked down by transfection of double-stranded siRNA. Because activin B acti-
vated the BMP pathway as shown above and because type I receptors determine signal specificity11–13, ALK1, 
ALK2, ALK3 and ALK6 are suggested to be candidate type I receptors for activin B. Significant expression of 
ALK1 and ALK6 was not detected in HepG2 cells (data not shown). Decreased expression of ALK2 or ALK3 by 
transfection with siRNA for ALK2 or ALK3, respectively (Supplementary Fig. S3A), decreased activin B-induced 
luciferase activity (Fig. 3A). However, ALK3 knockdown decreased the basal transcription of hepcidin, and 
responsiveness to activin B treatment was not decreased by ALK3 knockdown. Consistent with these results, 
knockdown of ALK3 decreased basal Smad1/5/8 phosphorylation, but significant increase in Smad1/5/8 phos-
phorylation in response to activin B was detected (Fig. 3B). By contrast, ALK2 knockdown did not affect the 
Figure 2. Induction of hepcidin by activin B in rat primary hepatocytes. (A–D) Rat primary hepatocytes 
were cultured in 0.2% FBS for 4 h, followed by treatment with activin B (2 nM) or BMP2 (4 nM) for the indicated 
time (A,B) or by treatment with various concentrations of activin B, i.e., 0, 0.125, 0.25, 0.5, 1 or 2 nM, or BMP2, 
i.e., 0, 0.25, 0.5, 1, 2 or 4 nM, for 1 h (D) or 8 h (C). (A,C) Hepcidin expression was examined by RT-qPCR 
analysis. Mean ± SE (n = 3). * and **P < 0.05 and P < 0.01, respectively, vs. cells treated without activin B or 
BMP2. (B,D) Phosphorylation of Smad1/5/8 and Smad2 as well as p38 and β -actin as the loading controls was 
examined by Western blot analysis. (E) Effect of cycloheximide was examined. Rat primary hepatocytes were 
stimulated with activin B (2 nM) or BMP2 (4 nM) in the presence or absence of cycloheximide (1 μ g/mL)  
for 8 h. Hepcidin expression was examined by RT-qPCR analysis. Mean ± SE (n = 3). **P < 0.01 vs. cells treated 
with the respective inhibitor (vehicle or CHX) but not with activin B or BMP2. ‡P < 0.01 vs. cells treated with 
the respective TGF-β family ligand (none, activin B or BMP2) but not with CHX. (F,G) HepG2 cells were 
transfected with the indicated reporters and CMV-β Gal. At 4 h post-transfection, cells were treated with or 
without activin A, activin AB or activin B for 12 h. Luciferase activity normalized to β -galactosidase activity was 
calculated. Mean ± SE (n = 3). (H) HepG2 cells were treated with increasing concentrations of activin A, activin 
AB or activin B, i.e., 0, 0.5, 1, 2 or 4 nM, for 1 h. Phosphorylation of Smad1/5/8, Smad2 and Smad3 as well as the 
loading control β -actin was examined by Western blot analysis. The cropped images of Western blot analysis are 
shown because of space liminations; images of the full-length blot are Supplementary Fig. S10.
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basal transcription of hepcidin (Fig. 3A) or the basal phosphorylation level of BR-Smad (Fig. 3B), but blunted 
responsiveness to activin B. These results suggest that ALK2 is a type I receptor that confers activin B-induced 
hepcidin transcription.
We also explored the type II receptors responsible for activin B-induced hepcidin transcription by 
down-regulating the expression of individual type II receptors (Supplementary Fig. S3B). As shown in Fig. 3C, 
knockdown of ActRIIA but not ActRIIB or BMPRII blunted the responsiveness of hepcidin transcription to 
activin B in HepG2 cells. Consistent with these results, activin B-induced phosphorylation of Smad1/5/8 was 
inhibited by ActRIIA knockdown (Fig. 3D). Hepa1-6 hepatoma cells lack significant expression of ActRIIA 
(Supplementary Fig. S4A). Although Hepa1-6 cells did not respond to activin B, forced expression of ActRIIA 
but not Tβ RII or BMPRII elicited efficient transcription of hepcidin by activin B; ActRIIB expression marginally 
increased hepcidin transcription (Supplementary Fig. S4B). These results suggest that ActRIIA is a main type II 
receptor for activin B-induced hepcidin transcription.
ALK4 and ActRIIs are required for activin B-induced AR-Smad-mediated signaling. Similar to 
activin A, activin B has been shown to signal via the type I receptor ALK4 and AR-Smad33,34. In addition, activin 
B can confer AR-Smad-mediated signaling via ALK721,33,34. We examined ALK4 and ALK7 expression in liver and 
liver-derived cells (Fig. 3E). RT-PCR analysis indicated that ALK4 was expressed in the liver, primary hepatocytes 
and HepG2 cells, whereas the ALK7 expression level was below the detection limit in the liver and liver-derived 
cells. Activin B-induced CAGA-luc transcription was increased in response to activin B, and the induction 
was decreased by expression of ALK4(KR), a kinase-inactive mutant of ALK4 that acts as a dominant-negative 
form34 (Fig. 3F). These results suggest that ALK4 is a receptor that confers the signal via AR-Smad. We further 
Figure 3. ALK2/ActRIIA and ALK4/ActRIIA/IIB mediate activin B-induced up-regulation of hepcidin and 
CTGT expression, respectively. (A–D,G) HepG2 cells were transfected with siRNA for the indicated gene. At 
48 h of transfection, cells were further transfected with the indicated reporter and CMV-β Gal (A,C,G). At 4 h 
of plasmid transfection, cells were treated with or without activin B (A: 0, 0.125, 0.25, 0.5, 1 or 2 nM; C and G: 
2 nM) for 12 h. Mean ± SE (n = 3). (B,D) At 48 h of post-transfection, cells were treated with or without activin 
B (2 nM) for 1 h. Phosphorylation of Smad1/5/8 and β -actin was examined by Western blot analysis.  
(E) Expression of receptors for the TGF-β family in the indicated tissues and cells was examined by RT-PCR.  
(F) HepG2 cells transfected with CAGA-luc and CMV-β Gal were co-transfected with or without expression 
vector for inhibin β B (activin B) and the indicated kinase-inactive activin receptor mutant for 16 h. Mean ± SE 
(n = 3). (H) Rat primary hepatocytes were treated with or without A-83-01 (5 μ M), followed by treatment with 
activin B (2 nM) for 8 h. Expression of CTGF was examined by RT-qPCR analysis. Mean ± SE (n = 3). *P < 0.05, 
vs. cells treated with the respective inhibitor but not with activin B. The cropped images of Western blot 
analysis and RT-PCR analysis are shown because of space liminations; images of the full-length blot and gel are 
Supplementary Fig. S11.
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explored the type II receptor responsible for activin B-mediated AR-Smad phosphorylation and activation by use 
of kinase-inactive mutant activin receptor and CAGA-luc. Expression of ActRIIB(KR) decreased the luciferase 
expression induced by activin B expression, and ActRIIA(KR) had a lesser potency to inhibit activin B-mediated 
CAGA-luc transcription (Supplementary Fig. S5A). Knockdown of ActRIIA or ActRIIB also decreased respon-
siveness to activin B to stimulate transcription of CAGA-luc (Fig. 3G). Previous studies have shown that expres-
sion of connective tissue growth factor (CTGF), a principle inducer of liver fibrogenesis35, is up-regulated by 
activated AR-Smad in hepatocytes36,37. To explore the role of activin B-induced phosphorylation of AR-Smad, we 
evaluated CTGF expression and the effects of A-83-01, an inhibitor of ALK4/5/7, to block AR-Smad-mediated 
signaling38. Activin B increased CTGF expression, and the up-regulation of CTGF expression was inhibited by 
A-83-01 in primary hepatocytes (Fig. 3H). As expected, A-83-01 blocked activin B-induced phosphorylation 
of Smad2 and Smad3 in primary hepatocytes (Supplementary Fig. S5B) and the transcription of CAGA-luc in 
HepG2 cells (Supplementary Fig. S5C).
Provided that activin B elicits BR-mediated signaling via ALK2 and ActRIIA and AR-mediated signaling via 
ALK4 and ActRIIs, we hypothesized that ALK2 forms complex with ALK4 as well as ActRII. We first evaluated 
complex formation of endogenous receptors by co-immunoprecipitation assay in HepG2 cells, but could not 
detect it because of insensitivity of the antibody. Thus, complex formation was examined in HepG2 cells expressed 
receptor encoding Flag-tagged ALK2, HA-tagged ALK4 or 6Myc-tagged ActRIIA. After cross-linking using 
BS3, a cell-impermeable cross-linker, cell lysates were immunoprecipitated with anti-Flag antibody, followed 
by Western blot. ALK2 specifically migrated at ~360 kDa (band 1), ~300 kDa (band 2), and ~140 kDa (band4) 
in a BS3-dependent manner (Supplementary Fig. S6A). In addition, Western blot analysis indicated the bands 
at ~360 kDa (band 1), ~300 kDa (band 2) and ~140 kDa (band 4) as the immunoreactive molecules for anti-HA 
antibody and at ~360 kDa (band 1) and ~160 kDa (band 3) as those for anti-Myc antibody. These results suggest 
that ALK2 intrinsically associate with ALK4 or ActRIIA or both; especially the band at ~360 kDa (band 1), which 
was the band with common size detected in Western blot using antibody against Flag, HA or Myc, may indicate 
receptor complex of ALK2-ALK4-ActRIIA. We also examined effect of activin B on receptor complex; treatment 
with activin B generally tended to decrease the intensity of slowly migrated-bands (Supplementary Fig. S6B). The 
reason is currently unknown. It is possible that activin B stimulates internalization of receptor complex; activin 
A-induced receptor internalization has been reported39,40. Future studies should clarify the mechanism underly-
ing the decreased band intensity.
Resistance to LDN-193189 by the formation of an ALK2 and ActRIIA receptor complex. LDN-
193189 is an inhibitor for type I receptors of the BMP pathway, i.e., ALK2, ALK3 and ALK615. Provided that ALK2 
is the principle receptor that confers activin B-induced hepcidin transcription, we expected that the up-regulation 
of hepcidin expression by activin B would be blocked by LDN-193189. BMP2-induced hepcidin expression was 
blocked by LDN-193189 in primary hepatocytes, but the up-regulation of hepcidin expression by activin B was 
LDN-193189-resistant (Fig. 4A). Consistent with these results, LDN-193189 did not inhibit activin B-induced 
Smad1/5/8 phosphorylation, whereas BMP-2-induced phosphorylation of Smad1/5/8 was inhibited by LDN-
193189 (Fig. 4B). LDN-193189 decreased basal transcription of hepcidin, but the responsiveness to activin B, 
i.e., fold-induction of hepcidin transcription due to activin B treatment was not decreased in HepG2 cells. The 
fold-induction of activin B in cells treated with vehicle and in those treated with LDN-193189 was 5.6 and 16.9, 
respectively (Supplementary Fig. S7A). By contrast, LDN-193189 inhibited the responsiveness to BMP-2 (5.7-fold 
and 1.4-fold, respectively, Supplementary Fig. S7A). Similarly, LDN-193189 decreased basal Smad1/5/8 phos-
phorylation levels. However, LDN-193189-treated cells still responded to activin B but not BMP-2 to induce 
phosphorylation of Smad1/5/8 (Supplementary Fig. S7B). LDN-193189 did not affect activin B-induced Smad2 
phosphorylation in primary hepatocytes (Fig. 4B) and HepG2 cells (Supplementary Fig. S7B).
Failure to inhibit activin B-mediated hepcidin gene induction and phosphorylation of BR-Smad by LDN-
193189 clearly contradicts the blockade of activin B-mediated hepcidin transcription by ALK2 knockdown. We 
hypothesized that ALK2 and ActRIIA complex formation may be responsible for resistance to inhibitory effects 
of LDN-193189. Overexpression of the type I receptor and the type II receptor induces ligand-independent phos-
phorylation of R-Smad41. Phosphorylation of Smad1 resulting from co-expression of ALK2 and ActRIIA was 
not inhibited by 100 nM of LDN-193189 in HepG2 cells, although 400 nM of LDN-193189 decreased Smad1 
phosphorylation levels in ALK2 and ActRIIA-expressing cells (Fig. 4C, lane 5–7). By contrast, Smad1 phospho-
rylation induced by the expression of ALK2(QD), a constitutively active ALK242, was decreased by 100 nM LDN-
193189 (Fig. 4C, lane 2 and 3). Consistent with these results, co-expression of ActRIIA blocked the inhibition of 
ALK2(QD)-mediated hepdicin transcription by LDN-193189 (Supplementary Fig. S7C). Activin B-induced for-
mation of ALK2 and ActRIIA may decrease the inhibitory effect of LDN-193189 on BR-Smad-mediated signaling.
Activin B-induced activation of the BMP pathway is not limited to liver-derived cells. We exam-
ined whether activin B-induced activation of the BMP pathway is limited to liver-derived cells. Phosphorylation of 
BR-Smad and AR-Smad in response to activin B was evaluated in C2C12 myogenic cells, 3T3-L1 adipogenic cells 
and RAW264.7 macrophage cells. As shown in Fig. 5A, activin B induced Smad1/5/8 phosphorylation in all three 
cell types. Activin B also stimulated phosphorylation of Smad2 in 3T3-L1 cells and RAW264.7 cells but not C2C12 
cells. Our previous study also showed inability of activin A to phosphorylate Smad2 in C2C12 cells43; it is possible 
that C2C12 cells are not target cells of activins. Transcription of hepcidin(-2018)-luc was increased by activin B 
in C2C12 cells and 3T3-L1 cells, which was blocked by BMP-RE mutations (Fig. 5B). Furthermore, activin B also 
up-regulated the expression of Id1, a BMP signaling target gene44, and stimulated the transcription of BRE-luc, a 
well-known BMP-responsive reporter45 (Fig. 5C and Supplementary Fig. S8). These results suggest that activin 
B-mediated activation of the BMP pathway is not limited to liver-derived cells but applicable to a wide range of cells.
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Discussion
Previously, activin B was thought to be induced in response to hepatic inflammation, and the induced activin B 
stimulated the expression of the iron-regulating hormone hepcidin19,21. However, the source of activin B and the 
detailed induction of hepcidin were unclear. Here, we clarify the signal transduction from sinusoids to paren-
chyma that is mediated by activin B in response to liver inflammation. Endothelial cells and Kupffer cells produce 
activin B during LPS-induced inflammation, and the induced activin B stimulates hepcidin production in liver 
parenchymal cells. ALK2 in concert with ActRIIA transmits the activin B signal to stimulate hepcidin transcrip-
tion through phosphorylation and activation of BR-Smad. Activin B also stimulates AR-Smad-mediated signaling 
through ALK4 and ActRIIs, leading to up-regulation of CTGF expression (Supplementary Fig. S9).
Previous studies have reported that hepcidin transcription is regulated by activin B, but conflicting mecha-
nisms were proposed19,21. Besson-Fournier et al.19 suggested ALK3 is the primary receptor that induces hepcidin 
transcription through activin B, whereas ALK2 was proposed to be the main receptor to confer activin B-induced 
hepcidin transcription21. The present results on the transcriptional regulation of hepcidin by activin B are consist-
ent with the results of Canali et al.21. It is unclear why the previous results are inconsistent. Besson-Fournier et al.19  
concluded that ALK3 transmits activin B-induced hepcidin expression because treatment with the extracellu-
lar region of ALK3 fused to an immunoglobulin Fc domain (ALK3-Fc) but not ALK2-Fc decreased the hepci-
din expression level in hepatocytes treated with activin B. The interpretation was that activin B was trapped by 
ALK3-Fc and could not be bound to ALK3 expressed at the cell surface. However, they did not examine hepcidin 
expression in ALK3-Fc-treated cells without activin B; it is possible that endogenously produced molecule(s) 
that induces hepcidin expression is trapped by ALK3-Fc. In fact, the present study revealed that ALK3 gene 
knockdown decreased the basal expression of hepcidin but did not affect responsiveness to activin B (Fig. 3A). 
ALK3-Fc is expected to also regulate hepcidin expression negatively, and to lead to the unaltered responsiveness 
to activin B.
There are points that are not consistent with the results of Canali et al.21. Consistent with previous results21,33,34, 
activin B induced AR-Smad phosphorylation and AR-Smad-mediated cell responses. Our results suggested that 
ALK4 confers activin B signaling in liver-derived cells. By contrast, provided that knockdown of ALK7 blunted 
activin B-induced phosphorylation of AR-Smad, Canali et al.21 suggested ALK7 as a receptor for activin B in 
HepB3 cells. However, ALK7 is expressed in a tissue-restricted manner46,47, and its expression in liver is rela-
tively low46,47. In fact, ALK7 expression in the liver and primary hepatocytes was below the detection limit in 
RT-PCR analysis, and it could not be detected in HepG2 cells and Hepa1-6 cells (Fig. 3E). We conclude that 
AR-Smad phosphorylation and activation mediated by ALK4 in response to activin B is physiologically relevant 
Figure 4. Activin B-mediated signaling is LDN-193189-insensitive. (A,B) Rat primary hepatocytes were 
treated with or without LDN-193189 (100 nM) for 15 min, followed by treatment with activin B (2 nM) or 
BMP2 (4 nM) for 1 h (B) or 8 h (A). Expression of hepcidin (A) was examined by RT-qPCR analysis. Mean ± SE 
(n = 3). * and **P < 0.05 and P < 0.01, respectively, vs. cells treated with the respective inhibitor but not 
with activin B. ‡P < 0.01 vs. cells treated with the respective TGF-β family ligand (none, activin B or BMP2) 
but not with LDN-193189. (B) Phosphorylation of Smad1/5/8 and Smad2 as well as p38 and β -actin as the 
loading controls was examined by Western blot analysis. (C) HepG2 cells were transfected with 6Myc-tagged 
Smad1 and the indicated HA-tagged ALK2 or ActRIIA. At 4 h post-transfection, cells were treated with or 
without LDN-193189 (− : 0 nM, + : 100 nM and + + : 400 nM) for 48 h. Smad1 protein expressed in cells was 
immunoprecipitated by use of an anti-c-Myc antibody, and BR-Smad phosphorylation was examined by 
Western blot analysis. The cropped images of Western blot analysis are shown because of space liminations; 
images of the full-length blot are Supplementary Fig. S12.
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in liver-derived cells. Canali et al.21 also suggested that activin B-induced BR-Smad signaling is limited to 
liver-derived cells. By contrast, our results clearly reveal the activation of the BMP pathway by activin B in several 
cell types.
In the canonical signal transduction of the TGF-β family described above, members of the TGF-β and activin 
subgroups signal through inducing AR-Smad phosphorylation, whereas the BMP subgroup signals though 
BR-Smad phosphorylation. The type I receptor determines the specificity of the signaling; ALK4/5/7 primarily 
phosphorylate AR-Smad, whereas ALK1/2/3/6 phosphorylate BR-Smad11–13. Previous studies have shown three 
types of non-canonical Smad signaling: (1) transient BR-Smad phosphorylation mediated by activated ALK5 in 
response to TGF-β 41,48–50, (2) TGF-β -induced transient phosphorylation of BR-Smad by ALK1 in an endothelial 
cell-restricted manner51, and (3) long-lasting AR-Smad phosphorylation by ALK3/6 in response to BMP41. In 
summary, a ligand uses a canonical type I receptor that phosphorylates a non-canonical R-Smad (case 1 and 3). 
In addition, a ligand can use a different class of receptor that phosphorylates the canonical R-Smad for the 
type I receptor. As a whole, the non-canonical R-Smads for the ligand are phosphorylated (case 2). The pres-
ent study reveals that activin B induces prolonged phosphorylation of the non-canonical BR-Smads via ALK2 
and stimulates BMP-regulated gene transcription, including hepcidin, not only in hepatocytes but also in 
non-hepatocytes. These results are consistent with case 2, and activin B induces non-canonical R-Smads medi-
ated by a non-canonical type I receptor. However, BR-Smad phosphorylation was not transient but long-lasting. 
Therefore, the non-canonical Smad phosphorylation shown here is a unique example.
In the current signaling model of the TGF-β family, the BMP type II receptors partly overlap with those of 
activin. ActRIIA and ActRIIB act as type II receptors for activin and BMP, although the type I receptors that con-
fer the signal are distinct between activin (ALK4/7) and BMP (ALK2/3/6)11–13. The present study indicates intrin-
sic complex formation of ALK2 with ALK4, and also suggests the inclusion of ActRIIA in the receptor complex. 
In view of the receptor complex tetramer formation, consisting of two type II receptors and two type I receptors, 
after ligand binding11–13, activin B may bind ALK2 and ALK4 together with ActRIIA and ActRIIB in a receptor 
complex to signal (Supplementary Fig. S9).
Treatment with the BMP receptor inhibitor LDN-193189 decreased the basal expression of hepcidin in HepG2 
cells. However, responsiveness to activin B but not BMP2, i.e., fold-induction of hepcidin transcription in response 
to activin B, was not decreased in primary hepatocytes and HepG2 cells, respectively (Supplementary Fig. S7A). 
Responsiveness to the molecules of interest should be evaluated as the fold-induction of expression and tran-
scription in non-treated cells52. Thus, we suggest that LDN-193189 simply decreased basal expression and tran-
scription of hepcidin and that LDN-193189-treated cells were still responsive to activin B. Besson-Fournier 
et al.19 suggested inhibition of activin B-induced hepcidin expression by LDN-193189 on the basis of the data that 
hepcidin expression was lower in cells treated with both activin B and LDN-193189 than in those treated with 
activin B alone. However, similar to the present study, basal expression of hepcidin, i.e., expression in cells treated 
Figure 5. Activin B-induced activation of the BMP pathway is not limited to liver-derived cells. (A) C2C12 
myogenic cells, 3T3-L1 preadipocytes and RAW264.7 macrophage cells were treated treatment with or without 
activin B (2 nM) for 1 h. Phosphorylation of Smad1/5/8 and Smad2 as well as β -actin as the loading control was 
examined by Western blot analysis. (B) C2C12 cells or 3T3-L1 cells were transfected with the indicated reporter 
and CMV-β Gal. At 24 h post-transfection, cells were treated with or without activin B (2 nM) for 24 h. Luciferase 
activity normalized to β -galactosidase activity was calculated, and the relative luciferase activity in cells treated 
without activin B was set at 1. Mean ± SE (n = 3). (C) C2C12, 3T3-L1 and RAW264.7 cells were treated with 
or without activin B (2 nM) for 4 h (C2C12 and 3T3-L1) or 8 h (RAW264.7). Expression of Id1 was examined 
by RT-qPCR analysis. The expression level in the control cells treated without activin B was set at 1. Mean ± SE 
(n = 3 for C2C12 and 3T3-L1, n = 4 for RAW264.7). **P < 0.01, vs. respective cells treated without activin B. 
The cropped images of Western blot analysis are shown because of space liminations; images of the full-length 
blot are Supplementary Fig. S13.
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without activin B, was also decreased by LDN-193189, and responsiveness to activin B was unaffected by LDN-
193189. Thus, although the present results on the role of LDN-193189 in hepcidin expression are consistent with 
the results by Besson-Fournier et al.19, the interpretation of the results is distinct.
We also showed that the effect of LDN-193189 to inhibit ALK2-mediated phosphorylation of BR-Smad and 
hepcidin transcription is diminished by ActRIIA expression. Previous studies have shown that in addition to 
ALK2/3/6 kinase activity15, LDN-193189 inhibits activity of ALK4/553 and ActRIIA54 serine/threonine kinases as 
well as the other kinases unrelated to TGF-β family signaling55. The present results on resistance of LDN-193189 
activity by co-expression of ALK2 and ActRIIA, however, can not be simply explained by inhibition of uninten-
tional kinase activity. It may be difficult for LDN-193189 to approach ALK2 to inhibit the serine/threonine kinase 
activity of ALK2 after complex formation with ActRIIA. The intracellular domain of ALK2 has higher affinity 
to ActRIIA than to ActRIIB56. It is possible that steady ALK2 and ActRIIA complex formation leads to relative 
resistance to LDN-193189.
The present study indicates that activin B simultaneously stimulates signaling via AR-Smad and BR-Smad, 
increasing expression of CTGF and hepcidin, respectively, in hepatocytes. As hepatitis triggers the onset 
of liver fibrosis57, inflammation-induced activin B could be one molecule that links inflammation to fibro-
sis, which is mediated by the induction of CTGF. In addition, activin B may be responsible for the onset of 
inflammation-induced anemia through the up-regulation of hepcidin expression. Thus, to prevent adverse effects 
on liver function, activin B induced by inflammation may be a possible therapeutic or preventive target.
Materials and Methods
Materials. Activin A and activin AB58 and anti-inhibin α , β A (GY) and β B (G544) antibodies59,60 were generously 
provided by Dr. Y. Hasegawa (Kitasato University). Activin A and activin AB were purified near homogeneity from 
bovine follicular fluid58. Amino acid sequence of mature region of bovine inhibin β A and β B is the same as human 
inhibin β A and β B, respectively. Recombinant human activin B and BMP2 were purchased from R & D Systems 
(Minneapolis, MN, USA); according to the manufacturer’s instruction, activin B and BMP2 were > 90% and > 95% 
purity assessed by SDS-PAGE, respectively. The following reagents were also purchased and used: lipopolysaccharide 
(LPS) from Pseudomonas aeruginosa 10 (L8643) was from Sigma (St. Louis, MO, USA); LDN-193189 was from 
Stemgent (San Diego, CA, USA); A83–01 was from Calbiochem (Darmstadt, Germany); rabbit polyclonal antibodies 
against phospho-Smad1 (Ser463/Ser465)/Smad5 (Ser463/Ser465)/Smad8 (Ser426/Ser428) (#9511), phospho-Smad2 
(Ser465/Ser467) (#3101) and p38 (#9212), and rabbit monoclonal antibody against phospho-Smad3 (Ser423/Ser425) 
(C25A9, #9520) were from Cell Signaling Technology (Danvers, MA, USA); rat monoclonal antibody against F4/80 
(CI:A3-1, ab6640), rabbit polyclonal antibody against CD31 (ab28364), and mouse monoclonal antibody against 
β -actin (AC-15, ab6276) was from Abcam (Cambridge, MA, USA); a rabbit polyclonal antibody against c-Myc 
(A-14, sc-789) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Plasmids. Constitutively active ALK2 and ALK3 were provided by Dr. K. Miyazono. Expression vectors for 
receptors of the TGF-β family and Smad were previously described41. The hepcidin reporter construct, i.e., the 
hepcidin promoter spanning nt −2018 to nt − 35 inserted into the luciferase reporter vector pGL4 (hepcidin 
(-2018)-luc), and the mutated plasmids were previously described52,61; the translational initiation site is defined as 
+ 1. Cytomegalovirus promoter-controlled β -galactosidase expression vector (CMV-β Gal) was used as a plasmid 
to correct transfection efficiency.
Animals and cell culture. Animal care and experiments were approved by Animal Care Committee of 
Kyoto University (27-43-2 and 27–72) and Institutional Animal Care and Use of Committee, Kitasato University 
(15-036), and all animal experiments were conducted in accordance with the approved guidelines. Primary hepat-
ocytes from male Sprague-Dawley rats were prepared as described previously61. HepG2 human hepatoma cells, 
Hepa1-6 mouse hepatoma cells, C2C12 mouse myoblasts, 3T3-L1 mouse preadipocytes and RAW264.7 mouse 
macrophage-like cells were cultured in DMEM with 10% heat-inactivated FBS and antibiotics.
Immunohistochemistry. To identify the localization of inhibin subunits in the liver, male C57BL/6 mice 
aged 9 wks were intraperitoneally injected with LPS (5 mg/kg) or phosphate-buffered saline (PBS) (n = 4). After 
6 h of injection, livers were fixed with Bouin’s solution, embedded in paraffin, and sectioned to 4 μ m thickness. 
Immunohistochemical analyses using anti-inhibin α , β A or β B antibody were performed as described by Asano 
et al.62.
siRNA transfection. HepG2 cells (7.2 × 105 per 60 mm dish) were transfected with 10 μ L of Lipofectamine 
RNAi Max (Invitrogen) and 200 pmol of siRNA according to the manufacturer’s protocol. After 24 h of siRNA 
transfection, cells were trypsinized, replated into 24-well plates or 12-well plates for 20 h, and used for subsequent 
experiments. The siRNA sequences are shown in Supplementary Table S1.
RNA isolation, RT-PCR and RT-quantitative PCR. Total RNA isolation, cDNA synthesis, PCR, and 
real-time quantitative PCR (qPCR) were performed as described previously61 with a modification; KOD-plus 
neo (TOYOBO, Osaka, Japan) was used as the DNA polymerase for PCR. The oligonucleotide primers used are 
presented in Supplementary Table S2. The ∆ ∆ Ct method was used to normalize the levels of target transcripts to 
GAPDH levels63.
Immunoprecipitation and Western blotting. HepG2 cells were transiently transfected with 
6Myc-tagged Smad1 with or without expression vectors for the type I receptors and type II receptors of the TGF-β 
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family. At 4 h post-transfection, cells were exposed to LDN-193189 for 48 h. Immunoprecipitation and Western 
blotting were performed as described previously64. The immunoreactive proteins were visualized using an ECL 
Select Western blotting detection system (GE Healthcare, Buckinghamshire, UK) according to the manufacturer’s 
protocol.
Luciferase-based reporter assay. HepG2 cells (6 × 104 per well) or Hepa1-6 cells (1 × 105 per well) seeded 
onto 24-well plates were transfected with hepcidin(-2018)-luc or the indicated reporter plasmid (0.5 μ g), indi-
cated expression plasmid, or empty plasmid (0.5 μ g), and β -galactosidase expression plasmid under the control 
of a cytomegalovirus-derived promoter (pCMV-β Gal, 0.1 μ g) using polyethylenimine Max reagent (Polysciences, 
Warrington, PA, USA). After 4 h of transfection, cells were treated with activin B or BMP2 for 12–16 h. Firefly 
luciferase activity was normalized to β -galactosidase activity as previously described41. Relative luciferase activity 
was calculated as the ratio of luciferase activity to β -galactosidase activity, and the activity in unstimulated cells 
without treatment with inhibitors was set at 1.
Statistical analyses. Data are expressed as the mean ± standard error (SE). Gene expression data were 
log-transformed to provide an approximation of a normal distribution before analyses. Differences between gene 
expression levels in tissues or cells were examined using unpaired t-tests. Differences of P < 0.05 were considered 
significant.
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